Sun-Novo: BTP4507 has received the notification of approval for clinical trials

Zhitong
2025.10.12 08:34
portai
I'm PortAI, I can summarize articles.

According to the Zhitong Finance APP, Sun-Novo announced that its subsidiary Jiangsu Novo Biotech Co., Ltd. has received the "Drug Clinical Trial Approval Notice" issued by the National Medical Products Administration. The clinical trial application for the company's research project BTP4507 has been approved. BTP4507 is intended for the treatment of patients with primary hypertension who have poor response to monotherapy

According to the Zhitong Finance APP, Sun-Novo (688621.SH) announced that its subsidiary Jiangsu Novo Biotech New Drug Research and Development Co., Ltd. has received the "Drug Clinical Trial Approval Notification" issued by the National Medical Products Administration. The clinical trial application for the company's research project BTP4507 has been approved. BTP4507 is intended for the treatment of patients with primary hypertension who have poor response to monotherapy

Source: Zhitong The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.